Novo Nordisk ADR (NYSE:NVO) traded at $117.43 at last check on current trade day and made a downward move of -1.96% on its previous day’s price.
Looking at the stock we see that its previous close was $119.78 and the beta (5Y monthly) reads 0.148 with the day’s price range being $117.1434 – $119.087. The company has a trailing 12-month PE ratio of 40.31. In terms of its 52-week price range, NVO has a high of $148.15 and a low of $92.94. The company’s stock has lost about -14.22% over that past 30 days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Novo Nordisk ADR has a market cap of $392.05 billion and is expected to release its quarterly earnings report on 2024-Nov-06. With its Forward Dividend at 1.45 and a yield of 1.23%, the company’s investors could be anxious for the NVO stock to gain ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of 0.89, with the EPS growth for the year raised at 3.37 for current year and 3.37 for next year.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at 10.61B, with a low of 10.33B and a high of 11.11B. The median projection represents growth squeezing down to 24.20% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 42.15B, or 27.20% up from figures reported last year.
On the other hand, looking at the outlook for the NVO stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 50% Sell.
Based on estimates by 5 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the Novo Nordisk ADR (NVO) stock as a Hold, while 4 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the NVO stock currently stands at 2.21, and the most recent price level today is -3.19% off its SMA20 and -8.84% from its 50-day simple moving average. The RSI (14) is pointing at 37.76 while the volatility over the past week is 1.02% and jumps to 1.43% over the past one month. The beta value is 0.42, while the average true range (ATR) is currently pointing at 2.63. The average price target for the stock over the next 12 months is $160, with the estimates having a low of $156 and a high of $160. These price ends are -32.85% and -36.25% off the today’s price level respectively, although investors could be excited at the prospect of a -36.25% if the NVO share price touches on the median price of $160.
Coming back to Novo Nordisk ADR (NYSE:NVO), we note that the average 3-month trading volume was 4.07 million, while that of the preceding 10-day period stands at 4.21 million. Current shares outstanding are 3.38 billion.
The insiders hold 0.02% of the company’s shares while institutions hold 10.06%. The data shows that short shares as of 2024-09-30, stood at 7.03 million at a short ratio of 1.82. This represents a 22.00 short interest in shares outstanding on 2024-09-30. Shares short rose in September from the previous month at 5.13 million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock 13.52% up in year-to-date price movement.
